Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 7/20 | 0.44 |
| ▸ | MGAM | O43451 | 6/20 | 0.44 |
| ▸ | AMY1A | P0DUB6 | 6/20 | 0.44 |
| ▸ | SI | P14410 | 6/20 | 0.44 |
| ▸ | MGAM2 | Q2M2H8 | 6/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.42 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.42 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | F12 | P00748 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | MIF | P14174 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2583961 | 0.89 | SLC9A1 (0.54) | SLC9A1DGAT1GAAMGAMAMY1A | |
| SCHEMBL7841328 | 0.82 | DGAT1 (0.49) | SLC9A1DGAT1GAAMGAMAMY1A | |
| SCHEMBL1520814 | 0.81 | DGAT1 (0.72) | SLC9A1CYP2D6MAPK1DGAT1GAA | |
| SCHEMBL11077694 | 0.80 | POLB (0.60) | SLC9A1CYP2D6MAPK1DGAT1GAA | |
| Hydrochloric Acid SCHEMBL2681010 | 0.79 | DGAT1 (0.70) | SLC9A1CYP2D6MAPK1DGAT1GAA | |
| Guanidine SCHEMBL811270 | 0.72 | CYP2D6 (0.61) | CYP2D6MAPK1GAAKMT2AF2 | |
| Phenazine SCHEMBL29879113 | 0.71 | KDM4E (0.58) | SLC9A1CYP2D6MAPK1GAANOD1 | |
| Phenazine SCHEMBL29609188 | 0.71 | KDM4E (0.58) | SLC9A1CYP2D6MAPK1GAANOD1 | |
| SCHEMBL16706437 | 0.70 | MGAM (0.77) | SLC9A1GAAMGAMAMY1ASI | |
| SCHEMBL7746353 | 0.70 | SLC9A1 (1.00) | SLC9A1MAPK1GAANOD1CXCL8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 525 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747382-A1 | COMPOSITIONS AND METHODS FOR MANAGEMENT OF WHITEFLY | Natural Resources Institute (GB) | 2026-05-27 | — | — | EP | claimed |
| WO-2026102563-A1 | DISUBSTITUTED PYRIMIDOPYRROLE ANALOG AND USE THEREOF | 深圳湾实验室坪山生物医药研发转化中心 | 2026-05-21 | — | — | WO | claimed |
| EP-4713320-A2 | BCAT2 INHIBITORS | Agios Pharmaceuticals, Inc. (US) | 2026-03-25 | — | — | EP | claimed |
| EP-4680755-A1 | METHOD FOR IMPROVING 2, 4 DIHYDROXYBUTYRIC ACID PRODUCTION AND YIELD | Adisseo France S.A.S. (FR) | 2026-01-21 | — | — | EP | claimed |
| EP-4667492-A2 | TARGETED LIPID PARTICLES FOR SYSTEMIC DELIVERY OF NUCLEIC ACID MOLECULES TO LEUKOCYTES | Ramot at Tel-Aviv University Ltd. (IL) | 2025-12-24 | — | — | EP | claimed |
| EP-4615416-A1 | SELF-ASSEMBLING LIPID NANOPARTICLES FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS | Ramot at Tel-Aviv University Ltd. (IL) | 2025-09-17 | — | — | EP | claimed |
| EP-3160448-B1 | LIPOSOMAL FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | UNIV RAMOT (IL) | 2025-08-06 | — | — | EP | claimed |
| US-20250194603-A1 | COMPOSITIONS AND METHODS FOR MANAGEMENT OF WHITEFLY | NAT RESOURCES INSTITUTE (GB) | 2025-06-19 | — | — | US | claimed |
| WO-2025128977-A1 | COMPOSITIONS AND METHODS FOR MANAGEMENT OF WHITEFLY | NATIONAL RESOURCES INSTITUTE (GB) | 2025-06-19 | — | — | WO | claimed |
| CN-119849726-A | Hidden function driven multi-objective path planning optimization method for multi-channel network | 烟台哈尔滨工程大学研究院 | 2025-04-18 | — | — | CN | claimed |
| WO-2016174611-A1 | PHARMACEUTICAL COMPOUND | VALLAURIX PTE. LTD. (SG) | 2016-11-03 | — | — | WO | claimed |
| EP-3088418-A1 | PHARMACEUTICAL COMPOUND | VALLAURIX PTE. LTD. (SG) | 2016-11-02 | — | — | EP | claimed |
| EP-3088417-A1 | PHARMACEUTICAL COMPOUND | VALLAURIX PTE. LTD. (SG) | 2016-11-02 | — | — | EP | claimed |
| US-20160137689-A1 | PEPTIDE-RESIN CONJUGATE AND USE THEREOF | CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S.A. | 2016-05-19 | — | — | US | claimed |
| EP-3010930-A1 | PEPTIDE-RESIN CONJUGATE AND USE THEREOF | Chemical & Biopharmaceutical Laboratories of Patras S.A. (GR) | 2016-04-27 | — | — | EP | claimed |
| WO-2014203193-A1 | PEPTIDE-RESIN CONJUGATE AND USE THEREOF | CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S.A. (GR) | 2014-12-24 | — | — | WO | claimed |
| EP-1363875-B1 | NOVEL BENZAMIDINE DERIVATIVES HAVING ANTI-INFLAMMATORY AND IMMUNOSUPPRESSIVE ACTIVITY | ROTTAPHARM SPA (IT) | 2008-08-06 | — | — | EP | claimed |
| US-20040110801-A1 | Novel benzamidine derivatives having anti-inflammatory and immunosuppressive | ROTTAPHARM BIOTECH S.R.L. (IT) | 2004-06-10 | — | — | US | claimed |
| EP-1363875-A2 | NOVEL BENZAMIDINE DERIVATIVES HAVING ANTI-INFLAMMATORY AND IMMUNOSUPPRESSIVE ACTIVITY | ROTTA RESEARCH LABORATORIUM S.P.A. (IT) | 2003-11-26 | — | — | EP | claimed |
| WO-2002070468-A2 | NOVEL BENZAMIDINE DERIVATIVES HAVING ANTI-INFLAMMATORY AND IMMUNOSUPPRESSIVE ACTIVITY | ROTTA RESEARCH LABORATORIUM S.P.A. (IT) | 2002-09-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137689-A1 | PEPTIDE-RESIN CONJUGATE AND USE THEREOF | ARGLU1, ARG1, NPR1 | SLC9A1 1457/4885CYP2D6 2800/4885MAPK1 1799/4885 |
| US-20040110801-A1 | Novel benzamidine derivatives having anti-inflammatory and immunosuppressive | HRH4, NAT1, HRH3 | SLC9A1 1705/4885CYP2D6 655/4885MAPK1 415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.